Skip to content

Net Income at other companies

Eli Lilly logo
Eli LillyLLY
$7.4B+168%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.03B+59.6%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
-$96.23M+15.8%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$122.93M+9.6%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$94.32M+12.9%
Regenxbio logo
RegenxbioRGNX
-$90.05M-1,580%

Segments

By segment

See full
Reportable Segment-$49.12M+5.3%

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$50.7M+3.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Cash & equivalents$77.8M-26.6%
Total debt$114.5M-5.5%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%
Free cash flow-$42.9M+16.3%

Valuation

See full
Market cap$574.36M+111%
Enterprise value$611.08M+113%
P/S124×+6.3×

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Debt / equity1.5×+0.4×
Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prime Medicine's net income?
Prime Medicine (PRME) reported net income of -$49.12M in Q1 2026.
How has Prime Medicine's net income changed year-over-year?
Prime Medicine's net income increased by 5.3% year-over-year, from -$51.89M to -$49.12M.
What is the long-term trend for Prime Medicine's net income?
Over 4 years (2021 to 2025), Prime Medicine's net income has grown at a 5.0% compound annual growth rate (CAGR), from -$165.37M to -$201.14M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.